Physician profile
Austin Replogle
NPI 1831840586
$8,259.56
in general payments reported to CMS, 2019-2025
26 companies · $2,299 in 2025
The $2,299 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $330 · 2023: $1,221 · 2024: $4,409 · 2025: $2,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,738 · Travel and Lodging: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,737.90 |
| Travel and Lodging | $1,191.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $1,649.37 | 2023-2024 | Nalu Neurostimulation System |
| Medtronic, INC. | $1,121.17 | 2024-2025 | Inceptiv, Intellis Adaptivestim, Vanta Adaptivestim |
| Boston Scientific Corporation | $806.23 | 2024-2025 | General - Pain Management, Intracept, Superion Indirect Decompression System |
| Abbvie INC. | $653.16 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $576.00 | 2022-2025 | Relistor |
| Forte Bio-Pharma LLC | $572.61 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Collegium Pharmaceutical, INC. | $482.86 | 2022-2025 | Belbuca, Xtampza, Nucynta |
| Mml US, INC. | $447.61 | 2023-2025 | Reactiv8 |
| Scilex Pharmaceuticals INC. | $388.78 | 2023-2025 | Ztlido |
| Valinor Pharma, LLC | $191.87 | 2023-2024 | Movantik |
| Si-Bone, INC. | $170.93 | 2022-2023 | |
| Spinal Simplicity, LLC | $165.36 | 2024-2025 | Ha Minuteman G3-R |
| Vertos Medical, INC. | $163.11 | 2024 | Mild Device Kit |
| Relievant Medsystems, INC. | $162.73 | 2023 | Intracept |
| Globus Medical, INC. | $135.68 | 2025 | Senza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik Nro, INC. | $104.95 | 2025 | Prospera |
| Averitas Pharma INC. | $82.01 | 2025 | Qutenza |
| Nevro Corp. | $65.64 | 2022-2024 | Senza |
| Horizon Therapeutics Plc | $57.83 | 2022 | |
| Curonix LLC | $49.26 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biohaven Pharmaceutical Holding Company LTD. | $46.87 | 2022 | |
| Amgen INC. | $45.54 | 2022 | |
| Pfizer INC. | $40.94 | 2023-2024 | |
| Depuy Synthes Sales INC. | $38.36 | 2023 | Monovisc, Orthovisc |
| Vertex Pharmaceuticals Incorporated | $24.71 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $15.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Replogle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.